With Pfizer’s final stake sale in the bag, the two Big Pharma companies behind Haleon’s genesis have formally parted ways with the standalone consumer health giant. | After charting similar moves ...
Bengaluru: Pfizer will divest its remaining stake in Haleon, marking its complete exit from the British consumer healthcare ...
Pfizer Inc. (PFE) agreed to sell its remaining stake worth $3.3 billion in Haleon PLC (HLN), marking its exit from the UK-based consumer ...
Pfizer still owns about 7.3% of the company making it the largest shareholder. GSK sold its remaining stake in May last year.
Pfizer sold its entire 7.3% shareholding in London-listed consumer-health company Haleon for a net sum of 2.5 billion pounds ($3.25 billion). Pfizer sold 618 million shares for 385 pence each. The ...
Pfizer is wrapping up its lucrative goodbye to Haleon, raising approximately $3.3 billion by offloading its remaining 7.3% ...
Pharmaceutical Technology on MSN1d
Curevo procures $110m and former-GSK exec for shingles vaccine candidateCurevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former ...
AllAfrica on MSN2d
GSK Rebrands to Haleon Kenya After SeparationUK drugmaker GlaxoSmithKline Limited (GSK) has rebranded to Haleon Kenya Limited, effective March 14, 2025.The rebrand comes after GSK transferred its consumer health business to Haleon to focus on ...
Pomerantz LLP announces that a class action lawsuit has been filed against GSK plc ("GSK" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback